{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:40:07Z","timestamp":1752075607076,"version":"3.41.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87546","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:05:14Z","timestamp":1752073514000},"source":"Crossref","is-referenced-by-count":0,"title":["Breast Cancer Surgery at a Tertiary Center in Greece: Clinicopathological Associations and Patient Outcomes"],"prefix":"10.7759","author":[{"given":"Stefanos","family":"Flindris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysoula","family":"Margioula-Siarkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Margioula-Siarkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Markozannes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Empliouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Tasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouela - Aliki","family":"Almperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Mponiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatios","family":"Petousis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Dinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl238","article-title":"Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists\u2019 Collaborative Group overview","volume":"17","author":"Clarke M","year":"2006","unstructured":"Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists\u2019 Collaborative Group overview. Ann Oncol. 2006, 17:x59-62. 10.1093\/annonc\/mdl238","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher B","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, et al.. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002, 347:1233-41. 10.1056\/NEJMoa022152","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby S","year":"2011","unstructured":"Darby S, McGale P, Correa C, et al.. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011, 378:1707-16. 10.1016\/S0140-6736(11)61629-2","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar WJ","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al.. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024, 22:331-57. 10.6004\/jnccn.2024.0035","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou CM","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, et al.. Molecular portraits of human breast tumours. Nature. 2000, 406:747-52. 10.1038\/35021093","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat A","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, et al.. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015, 24:S26-35. 10.1016\/j.breast.2015.07.008","journal-title":"Breast"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie T","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, et al.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98:10869-74. 10.1073\/pnas.191367098","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02329-3","article-title":"Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial","volume":"22","author":"Abdel-Rahman O","year":"2020","unstructured":"Abdel-Rahman O, Tang PA, Cheung WY. Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial. Clin Transl Oncol. 2020, 22:1885-91. 10.1007\/s12094-020-02329-3","journal-title":"Clin Transl Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032063","article-title":"Superior survival for breast-conserving therapy over mastectomy in patients with breast cancer: a population-based SEER database analysis across 30 years","volume":"12","author":"Ke S","year":"2022","unstructured":"Ke S, Wang W, Li B, Feng X, Yan D, Liu J. Superior survival for breast-conserving therapy over mastectomy in patients with breast cancer: a population-based SEER database analysis across 30 years. Front Oncol. 2022, 12:1032063. 10.3389\/fonc.2022.1032063","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.02.006","article-title":"A reappraisal of the comparative effectiveness of lumpectomy versus mastectomy on breast cancer survival: a propensity score-matched update from the National Cancer Data Base (NCDB)","volume":"19","author":"Landercasper J","year":"2019","unstructured":"Landercasper J, Ramirez LD, Borgert AJ, Ahmad HF, Parsons BM, Dietrich LL, Linebarger JH. A reappraisal of the comparative effectiveness of lumpectomy versus mastectomy on breast cancer survival: a propensity score-matched update from the National Cancer Data Base (NCDB). Clin Breast Cancer. 2019, 19:e481-93. 10.1016\/j.clbc.2019.02.006","journal-title":"Clin Breast Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30067-5","article-title":"10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study","volume":"17","author":"van Maaren MC","year":"2016","unstructured":"van Maaren MC, de Munck L, de Bock GH, et al.. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016, 17:1158-70. 10.1016\/S1470-2045(16)30067-5","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24094","article-title":"Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation","volume":"115","author":"Freedman GM","year":"2009","unstructured":"Freedman GM, Anderson PR, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009, 115:946-51. 10.1002\/cncr.24094","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc KD","year":"2010","unstructured":"Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010, 28:1684-91. 10.1200\/JCO.2009.24.9284","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart MJ","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353:1659-72. 10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.14.1143","article-title":"Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial","volume":"92","author":"van Dongen JA","year":"2000","unstructured":"van Dongen JA, Voogd AC, Fentiman IS, et al.. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000, 92:1143-50. 10.1093\/jnci\/92.14.1143","journal-title":"J Natl Cancer Inst"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040587","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","volume":"351","author":"Hughes KS","year":"2004","unstructured":"Hughes KS, Schnaper LA, Berry D, et al.. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004, 351:971-7. 10.1056\/NEJMoa040587","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano AE","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al.. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017, 318:918-26. 10.1001\/jama.2017.11470","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey JC","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al.. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013, 310:1455-61. 10.1001\/jama.2013.278932","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn T","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al.. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013, 14:609-18. 10.1016\/S1470-2045(13)70166-9","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znac217","article-title":"Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey","volume":"109","author":"Gasparri ML","year":"2022","unstructured":"Gasparri ML, de Boniface J, Poortmans P, et al.. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022, 109:857-63. 10.1093\/bjs\/znac217","journal-title":"Br J Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16143-6","article-title":"Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy","volume":"31","author":"Limberg JN","year":"2024","unstructured":"Limberg JN, Jones T, Thomas SM, et al.. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol. 2024, 31:8813-20. 10.1245\/s10434-024-16143-6","journal-title":"Ann Surg Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini OD","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, et al.. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023, 9:1557-64. 10.1001\/jamaoncol.2023.3759","journal-title":"JAMA Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston SR","year":"2023","unstructured":"Johnston SR, Toi M, O'Shaughnessy J, et al.. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023, 24:77-90. 10.1016\/S1470-2045(22)00694-5","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s J","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022, 386:1143-54. 10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz SA","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023, 401:105-17. 10.1016\/S0140-6736(22)02420-5","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt AN","year":"2021","unstructured":"Tutt AN, Garber JE, Kaufman B, et al.. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021, 384:2394-405. 10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-019-00968-9","article-title":"Oncoplastic breast reconstruction in conservation surgery: steps to follow for a successful work","volume":"10","author":"Franceschini G","year":"2019","unstructured":"Franceschini G, Masetti R. Oncoplastic breast reconstruction in conservation surgery: steps to follow for a successful work. Indian J Surg Oncol. 2019, 10:660-1. 10.1007\/s13193-019-00968-9","journal-title":"Indian J Surg Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4991-8","article-title":"Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature","volume":"173","author":"Offodile AC 2nd","year":"2019","unstructured":"Offodile AC 2nd, Gu C, Boukovalas S, Coroneos CJ, Chatterjee A, Largo RD, Butler C. Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2019, 173:65-77. 10.1007\/s10549-018-4991-8","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379455-breast-cancer-surgery-at-a-tertiary-center-in-greece-clinicopathological-associations-and-patient-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:05:14Z","timestamp":1752073514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379455-breast-cancer-surgery-at-a-tertiary-center-in-greece-clinicopathological-associations-and-patient-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.87546","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}